Given the need for additional trials and no short/medium term prospect of significant inflows, MSB needs to raise something now in the order of $150m at least, with a further similar raise to come later (hopefully at a higher valuation) before it has any prospect of becoming cash flow positive.
And for the reasons you give, I see little prospect of that occurring by way of a conventional placement. Another US$40m or so in debt is simply not going to cut it.
Maybe a partnership? Apart from the fact that the few partnerships have not yet generated that kind of cash (save for the Cephalon deal some 11 years ago), MSB's track record in this area has not been good with Novartis, Mallinckrodt and Celgene all walking (and we don't know how many others had a look and declined the opportunity - certainly the company has long spruiked the high levels of interest from potential partners so presumably there must be lots more).
- Forums
- ASX - By Stock
- MSB
- RWE for 2nd MSB COVID-19 ARDS P3 Trial
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-426
-
-
- There are more pages in this discussion • 480 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 27197 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 43578 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 31763 | 1.100 |
2 | 33264 | 1.090 |
2 | 18897 | 1.085 |
2 | 18926 | 1.080 |
1 | 18000 | 1.075 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 23400 | 3 |
1.135 | 1090 | 1 |
1.140 | 65000 | 4 |
1.145 | 64500 | 3 |
1.150 | 92314 | 9 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |